The iconic rise of Viagra has firmly established as a benchmark of pharmaceutical success, yet its future within the broader sector now triggers questions about future returns . Generic versions are eroding exclusivity , causing worries that investing in companies significantly dependent to Viagra's former standing could be a problematic strategy,